Clinical trials: Alzheimer's Type
Alzheimer's Disease
Nefiracetam in the Treatment of Alzheimer's Disease
Some of the thinking difficulties of Alzheimer's patients may be due to a deficiency in a brain chemical called acetylcholine, which helps transmit messages between nerve cells.
- Trial name
- NCT00001933
- Testing
- Nefiracetam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Dementia, Alzheimer Type
TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
The primary objective of the study is to investigate the effects of oral TRx0014 at three doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type.
- Trial name
- NCT00515333
- Testing
- TRx0014
- Volunteers
- 323 people
- Sponsor
- TauRx Therapeutics Ltd
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjects with agitation associated…
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
- Trial name
- ACCORD (NCT04797715)
- Testing
- AXS-05
- Where
- 63 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Axsome Therapeutics, Inc.
Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment
Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to…
- Conditions
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- Trial name
- DIALCAT (NCT03578991)
- Testing
- Smart pillbox, Interactive digital platform
- Where
- 8 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Parc Sanitari Pere Virgili
Alzheimer Disease 3, Epilepsy
Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy
Participants will perform Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Alzheimer's disease assessment scale-cognitive section (ADAS-Cog), Hamilton Anxiety Scale…
- Trial name
- NCT05969054
- Testing
- Lacosamide 100 mg, Levetiracetam 250mg
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Xiangya Hospital of Central South University
Alzheimer Disease, Dementia Alzheimer Type
Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)
Alzheimer's disease (AD), one of the most common causes of dementia in Singapore and the developed world, is a neurodegenerative disorder with high socioeconomic impact. Accumulation of neurotoxic proteins (ie.
- Conditions
- Alzheimer Disease, Dementia Alzheimer Type, Dementia Alzheimer's Type, Alzheimer's Disease
- Trial name
- CLyVeB-AD-1 (NCT06965062)
- Testing
- Deep cervical lymph node to venous bypass (DCLNV-BP)
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- Vincent Tay Khwee Soon
Dementia, Alzheimer's Type, Alzheimer's Disease
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants.
- Trial name
- TREMHANCE (NCT07688213)
- Testing
- SAR448851
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Alzheimer's Disease
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease.
- Trial name
- NCT00814801
- Testing
- Galantamine 16 mg/day, Galantamine 24 mg/day
- Where
- Japan
- Volunteers
- 580 people
- Sponsor
- Janssen Pharmaceutical K.K.
Dementia of Alzheimer Type, Dementia
How Does Pianistic Musical Training Influence the Development of Alzheimer's Disease?
The goal of this clinical trial is to learn about and describe how pianistic training influences the development of Alzheimer's disease.
- Conditions
- Dementia of Alzheimer Type, Dementia, Dementia, Vascular, Dementia, Mixed
- Trial name
- NCT06378372
- Testing
- Music therapy based on piano learning
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- David Franco Castellanos
Dementia, Alzheimer Type
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
The primary objective of the study is to compare the efficacy of aripiprazole with placebo in patients with psychosis associated with Alzheimer's dementia.
- Trial name
- NCT01438060
- Testing
- Aripiprazole (BMS-337039)
- Volunteers
- 232 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mild, Moderate, or Severe Alzheimer's Disease
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
- Trial name
- NCT06745583
- Testing
- EI-1071 tablet, oral
- Where
- 2 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Elixiron Immunotherapeutics Inc.
Dementia of Alzheimer Type, Alzheimer Disease
Prevalence of Alzheimer's Disease Pathology in the Community
The goal of this observational study is to (I) study the proportion of people with Alzheimer's disease pathology in a large Norwegian population-based cohort of people aged 70 years or older and to (II) study longitudinal changes…
- Conditions
- Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment, Pathology
- Trial name
- HUNT4AD (NCT06719453)
- Volunteers
- 9,663 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Alzheimer's Type Dementia
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.
- Trial name
- NCT01539031
- Testing
- E2020
- Where
- 54 sites in Japan
- Volunteers
- 351 people
- Sponsor
- Eisai Co., Ltd.
Agitation Associated With, Alzheimer's Disease
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01922258
- Testing
- Brexpiprazole, OPC-34712
- Where
- 70 sites in United States, Bulgaria and 7 more
- Volunteers
- 270 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease, Mild Cognitive Impairment
tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia
There are currently no disease-modifying treatments for cognitive and behavioral symptoms associated with early clinical Alzheimer's disease (AD), and only minimally effective symptomatic treatments are available.
- Trial name
- NCT04507815
- Testing
- Active Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Alzheimer Disease, Dementia, Alzheimer Type
Deep Brain Stimulation for Alzheimer's Disease
Background: Deep brain stimulation (DBS) is used to modulate the activity of dysfunctional brain circuits. The safety and preliminary efficacy of nucleus basalis of Meynert (NBM)-DBS in Alzheimer's disease (AD) is proved in a…
- Conditions
- Alzheimer Disease, Dementia, Alzheimer Type, Deep Brain Stimulation
- Trial name
- NCT03959124
- Testing
- Deep brain stimulation, Best medical treatment for Alzheimer's disease
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Buddhist Tzu Chi General Hospital
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Hearing Loss, Sensorineural, Dementia of Alzheimer Type
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
This current translational project, funded by NIH, aims to better understand the impact of various signal modification strategies for older adults with Alzheimer's dementia and its potential precursor, known as amnestic mild…
- Conditions
- Hearing Loss, Sensorineural, Dementia of Alzheimer Type, Amnestic Mild Cognitive Impairment
- Trial name
- NCT04240561
- Testing
- High level of signal manipulation, Low level of signal manipulation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
- Trial name
- ACCORD-2 (NCT04947553)
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 456 people
- Sponsor
- Axsome Therapeutics, Inc.
Agitation in Patients With Dementia of the Alzheimer's Type
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.
- Trial name
- NCT02446132
- Testing
- AVP-786
- Where
- 227 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,197 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.